Role of Murine Leukemia Virus Reverse Transcriptase Deoxyribonucleoside Triphosphate-Binding Site in Retroviral Replication and In Vivo Fidelity

ABSTRACT Retroviral populations exhibit a high evolutionary potential, giving rise to extensive genetic variation. Error-prone DNA synthesis catalyzed by reverse transcriptase (RT) generates variation in retroviral populations. Structural features within RTs are likely to contribute to the high rate of errors that occur during reverse transcription. We sought to determine whether amino acids within murine leukemia virus (MLV) RT that contact the deoxyribonucleoside triphosphate (dNTP) substrate are important for in vivo fidelity of reverse transcription. We utilized the previously described ANGIE P encapsidating cell line, which expresses the amphotropic MLV envelope and a retroviral vector (pGA-1). pGA-1 expresses the bacterial β-galactosidase gene (lacZ), which serves as a reporter of mutations. Extensive mutagenesis was performed on residues likely to interact with the dNTP substrate, and the effects of these mutations on the fidelity of reverse transcription were determined. As expected, most substitution mutations of amino acids that directly interact with the dNTP substrate significantly reduced viral titers (>10,000-fold), indicating that these residues played a critical role in catalysis and viral replication. However, the D153A and A154S substitutions, which are predicted to affect the interactions with the triphosphate, resulted in statistically significant increases in the mutation rate. In addition, the conservative substitution F155W, which may affect interactions with the base and the ribose, increased the mutation rate 2.8-fold. Substitutions of residues in the vicinity of the dNTP-binding site also resulted in statistically significant decreases in fidelity (1.3- to 2.4-fold). These results suggest that mutations of residues that contact the substrate dNTP can affect viral replication as well as alter the fidelity of reverse transcription.

[1]  Miguel Ángel Martínez,et al.  Mutational analysis of Phe160 within the "palm" subdomain of human immunodeficiency virus type 1 reverse transcriptase. , 1999, Journal of molecular biology.

[2]  P. Charneau,et al.  A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G-->A hypermutation during negative-strand viral DNA synthesis. , 1995, Virology.

[3]  B. Larder,et al.  Mutational analysis of two conserved sequence motifs in HIV‐1 reverse transcriptase , 1991, FEBS letters.

[4]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[5]  L. Loeb,et al.  Human Immunodeficiency Virus Reverse Transcriptase , 1996, The Journal of Biological Chemistry.

[6]  W. C. Drosopoulos,et al.  Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase , 1996, Journal of virology.

[7]  L. Loeb,et al.  Fidelity of mutant HIV-1 reverse transcriptases: interaction with the single-stranded template influences the accuracy of DNA synthesis. , 1998, Biochemistry.

[8]  M. Modak,et al.  Elucidation of the role of Arg 110 of murine leukemia virus reverse transcriptase in the catalytic mechanism: biochemical characterization of its mutant enzymes. , 1996, Biochemistry.

[9]  M. Wainberg,et al.  Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2',3'-dideoxycytidine 5'-triphosphate and other drugs. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[11]  S. Goff,et al.  Replication Defect of Moloney Murine Leukemia Virus with a Mutant Reverse Transcriptase That Can Incorporate Ribonucleotides and Deoxyribonucleotides , 1998, Journal of Virology.

[12]  M. Bakhanashvili,et al.  Mutational studies of human immunodeficiency virus type 1 reverse transcriptase : the involvement of residues 183 and 184 in the fidelity of DNA synthesis , 1996, FEBS letters.

[13]  M. Tisdale,et al.  Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89 , 1997, Antimicrobial agents and chemotherapy.

[14]  V. Pathak,et al.  Development of an In Vivo Assay To Identify Structural Determinants in Murine Leukemia Virus Reverse Transcriptase Important for Fidelity , 2000, Journal of Virology.

[15]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[16]  S. Montaño,et al.  Crystal structures of an N-terminal fragment from Moloney murine leukemia virus reverse transcriptase complexed with nucleic acid: functional implications for template-primer binding to the fingers domain. , 2000, Journal of molecular biology.

[17]  W A Hendrickson,et al.  Conferring RNA polymerase activity to a DNA polymerase: a single residue in reverse transcriptase controls substrate selection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Wainberg,et al.  Enhanced Fidelity of 3TC-Selected Mutant HIV-1 Reverse Transcriptase , 1996, Science.

[19]  V. Pandey,et al.  Functional Analysis of Amino Acid Residues Constituting the dNTP Binding Pocket of HIV-1 Reverse Transcriptase* , 1998, The Journal of Biological Chemistry.

[20]  V. Pathak,et al.  Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication , 1996, Journal of virology.

[21]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[22]  S. Sarafianos,et al.  Glutamine 151 participates in the substrate dNTP binding function of HIV-1 reverse transcriptase. , 1995, Biochemistry.

[23]  H. Temin,et al.  Retrovirus variation and reverse transcription: abnormal strand transfers result in retrovirus genetic variation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Merigan,et al.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy , 1996, Journal of virology.

[25]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  I Sauvaget,et al.  Identification of four conserved motifs among the RNA‐dependent polymerase encoding elements. , 1989, The EMBO journal.

[27]  D. Littman,et al.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range , 1991, Journal of virology.

[28]  B. Chesebro,et al.  Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus. , 1983, Virology.

[29]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[30]  Samuel H. Wilson,et al.  Vertical-scanning Mutagenesis of a Critical Tryptophan in the Minor Groove Binding Track of HIV-1 Reverse Transcriptase , 1998, The Journal of Biological Chemistry.

[31]  E. De Clercq,et al.  Anti-Human Immunodeficiency Virus Drug Combination Strategies , 1998, Antiviral chemistry & chemotherapy.

[32]  T. Darden,et al.  Reduced Frameshift Fidelity and Processivity of HIV-1 Reverse Transcriptase Mutants Containing Alanine Substitutions in Helix H of the Thumb Subdomain (*) , 1995, The Journal of Biological Chemistry.

[33]  E. Domingo,et al.  Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. , 1997, Nucleic acids research.

[34]  G. Saunders,et al.  Salt-induced structural changes in nucleosomes. , 1977, Nucleic acids research.

[35]  M A Wainberg,et al.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine , 1994, Antimicrobial Agents and Chemotherapy.

[36]  Brendan A. Larder,et al.  Site-specific mutagenesis of AIDS virus reverse transcriptase , 1987, Nature.

[37]  H. Mitsuya,et al.  Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′,3′-Dideoxynucleoside 5′-Triphosphates (*) , 1995, The Journal of Biological Chemistry.

[38]  V. Pathak,et al.  The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate , 1997, Journal of virology.

[39]  S. Sarafianos,et al.  Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Ortín,et al.  Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance. , 1986, Nucleic acids research.

[41]  E. Wimmer,et al.  A segment of the 5' nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation , 1988, Journal of virology.

[42]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[43]  G. Gerard,et al.  Substrate binding domain of murine leukemia virus reverse transcriptase. Identification of lysine 103 and lysine 421 as binding site residues. , 1988, The Journal of biological chemistry.

[44]  V. Pathak,et al.  E- vectors: development of novel self-inactivating and self-activating retroviral vectors for safer gene therapy , 1995, Journal of virology.

[45]  E. Domingo,et al.  Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. , 1996, The EMBO journal.

[46]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[47]  W A Hendrickson,et al.  Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. , 1995, Structure.

[48]  N. Rege,et al.  Role of glutamine-151 of human immunodeficiency virus type-1 reverse transcriptase in RNA-directed DNA synthesis. , 1997, Biochemistry.

[49]  D. Housman,et al.  Ouabain resistance conferred by expression of the cDNA for a murine Na+, K+-ATPase alpha subunit. , 1987, Science.

[50]  K. Singh,et al.  Analysis of the Role of Glutamine 190 in the Catalytic Mechanism of Murine Leukemia Virus Reverse Transcriptase* , 1999, The Journal of Biological Chemistry.

[51]  S. Sarafianos,et al.  Site-directed Mutagenesis of Arginine 72 of HIV-1 Reverse Transcriptase , 1995, The Journal of Biological Chemistry.